Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pariente
Edouard Louis

Showing results (311-320 of 364) with videos related to

Pageof 37
Sort By:
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Gut|January 29, 2011
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapyJean-François Rahier, Pavol Papay, Julia Salleron, et al.
Lancet (London, England)|April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G Feagan, William J Sandborn, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.
The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Inflammatory Bowel Diseases|June 2, 2017
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel DiseaseAnthony Buisson, Florent Gonzalez, Florian Poullenot, et al.
The American Journal of Gastroenterology|November 6, 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAIDConstance Chapuis-Biron, Julien Kirchgesner, Benjamin Pariente, et al.
Oncotarget|March 15, 2018
Innovative methodology for the identification of soluble biomarkers in fresh tissuesBrunella Costanza, Andrei Turtoi, Akeila Bellahcène, et al.
Journal of Crohn'S & Colitis|September 13, 2020
Solute carrier family 12 member 2 as a proteomic and histological biomarker of dysplasia and neoplasia in ulcerative colitisAngela-Maria Merli, Sophie Vieujean, Charlotte Massot, et al.
Gut|January 26, 2017
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) studyYoram Bouhnik, Franck Carbonnel, David Laharie, et al.
Pageof 37

Showing results (311-320 of 364) with videos related to

Sort By:
Pageof 37
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Gut|January 29, 2011
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapyJean-François Rahier, Pavol Papay, Julia Salleron, et al.
Lancet (London, England)|April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G Feagan, William J Sandborn, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.
The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Inflammatory Bowel Diseases|June 2, 2017
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel DiseaseAnthony Buisson, Florent Gonzalez, Florian Poullenot, et al.
The American Journal of Gastroenterology|November 6, 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAIDConstance Chapuis-Biron, Julien Kirchgesner, Benjamin Pariente, et al.
Oncotarget|March 15, 2018
Innovative methodology for the identification of soluble biomarkers in fresh tissuesBrunella Costanza, Andrei Turtoi, Akeila Bellahcène, et al.
Journal of Crohn'S & Colitis|September 13, 2020
Solute carrier family 12 member 2 as a proteomic and histological biomarker of dysplasia and neoplasia in ulcerative colitisAngela-Maria Merli, Sophie Vieujean, Charlotte Massot, et al.
Gut|January 26, 2017
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) studyYoram Bouhnik, Franck Carbonnel, David Laharie, et al.
Pageof 37